Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Indaptus Therapeutics Inc INDP

Healthcare Biotechnology
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be... see more

Recent & Breaking News (NDAQ:INDP)

Intec Pharma Announces Proposed Public Offering

PR Newswire January 30, 2020

Intec Pharma Issues Letter to Shareholders

PR Newswire January 9, 2020

Intec Pharma Provides Update on Novartis Feasibility and Option Agreement

PR Newswire December 11, 2019

Intec Pharma to Present at LD Micro's 12th Annual Main Event

PR Newswire December 6, 2019

Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital

PR Newswire December 3, 2019

Intec Pharma to Participate in Jefferies London Healthcare Conference

PR Newswire November 13, 2019

Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

PR Newswire November 12, 2019

Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society

PR Newswire September 25, 2019

Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society

PR Newswire September 16, 2019

Intec Pharma to Participate in September Investment Conferences

PR Newswire September 3, 2019

Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update

PR Newswire August 9, 2019

Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

PR Newswire July 22, 2019

Horizons ETFs Rebalances Marijuana-Focused ETFs

Canada NewsWire July 3, 2019

Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery

PR Newswire July 1, 2019

Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

PR Newswire June 25, 2019

Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders

PR Newswire June 19, 2019

Intec Pharma to Participate at June Investment Conferences

PR Newswire May 28, 2019

Intec Pharma Granted European Patent

PR Newswire May 20, 2019

Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update

PR Newswire May 7, 2019

Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders

PR Newswire May 2, 2019